Loading viewer...
conference
Format: PDF conference
Karyopharm Therapeutics presented clinical and commercial updates on XPOVIO (selinexor) for relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma at the 2020 American Society of Hematology conference. The presentation discusses regulatory strategies, clinical trial designs, and the commercial potential of selinexor alongside other investigational drug candidates.
conference
34 Pages
conference
41 Pages
Oshkosh Corporation
Regeneron Pharmaceuticals 2023 JPMorgan Healthcare Conference Strategy Update
conferenceconference
37 Pages
Regeneron Pharmaceuticals, Inc.
CapitaLand Investment Limited 2023 BofA ASEAN Conference
conferenceconference
56 Pages
CapitaLand Investment Limited